RecruitingPHASE1, PHASE2NCT06011109

Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab

Studying Glial tumor

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Aveta Biomics, Inc.
Principal Investigator
Nicole Shonka, MD, MD
University of Nebraska
Intervention
APG-157(drug)
Enrollment
30 target
Eligibility
19 years · All sexes
Timeline
2023 – 2026

Study locations (2)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06011109 on ClinicalTrials.gov

Other trials for Glial tumor

Additional recruiting or active studies for the same condition.

See all trials for Glial tumor →

← Back to all trials